Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model

Yusuke Narita¹,²§, Kiyoshi Okamoto¹, Megumi Ikemori Kawada¹, Kazuma Takase¹, Yukinori Minoshima¹, Kotaro Kodama¹, Masao Iwata¹, Norimasa Miyamoto¹,² and Kohei Sawada¹,²

¹Eisai Co., Ltd., Tsukuba, Ibaraki, Japan. ²Genomics-Based Drug Discovery, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Running title: E6201 treatment for acquired resistance to vemurafenib

Key words: vemurafenib, acquired resistance, MEK1 secondary mutation, E6201, ATP-competitive MEK inhibitor
Financial support: All authors received financial support by Eisai Co., Ltd.

§Corresponding author: Yusuke Narita, Oncology, Eisai Co., Ltd., 5-1-3, Tokodai, Tsukuba, Ibaraki 300-2635, Japan. Phone: 81-29-847-5291; Fax: 81-29-847-2037; E-mail: y-narita@hhc.eisai.co.jp.

Potential conflict of interest: All authors are employees of Eisai Co., Ltd.

Word count: 4007 words

Number of figures and tables: 6 figures
Abstract

Many clinical cases of acquired resistance to the BRAF inhibitor vemurafenib have recently been reported. One of the causes of this acquired resistance is the BRAF downstream kinase point mutation MEK1-C121S. This mutation confers resistance to not only vemurafenib, but also to the allosteric MEK inhibitor selumetinib (AZD6244). Here, we investigated the pharmacological activities and effectiveness of the novel MEK inhibitor E6201 against BRAF-V600E mutant melanoma harboring the MEK1-C121S mutation. A cell-free assay confirmed that E6201 is an ATP-competitive MEK inhibitor meaning it has a different binding mode with MEK compared with allosteric MEK inhibitors. E6201 is more effective against BRAF-V600E mutant melanoma compared with BRAF wild-type melanoma based on MEK inhibition. We found that the acquired MEK1-C121S mutation in BRAF-V600E mutant melanoma conferred resistance to both vemurafenib and selumetinib but not E6201. The effectiveness of E6201 in this preclinical study is a result of its binding with MEK1 far from the C121S point mutation so the mutation is unable to influence the MAPK pathway inhibitory activity. These results support further clinical investigation of E6201.
Introduction

In certain types of cancer, the activation of kinases is known to have a role in oncogenicity (1). Therefore, kinase inhibitors are an attractive option for use as cancer chemotherapy (2). These drugs confer a survival benefit to cancer patients; however, a number of mechanisms of acquired resistance to kinase inhibitors have been reported (3, 4). For example, gatekeeper mutations that confer resistance to kinase inhibitors frequently occur in EGFR (5, 6) and BCR-ABL (7).

Metastatic melanoma patients have a very poor prognosis with a median survival time of only 6 to 10 months (8). The BRAF-V600E mutation occurs in approximately 50% of melanomas, and this mutation is strongly associated with tumorigenicity (8, 9). Recently, a clinical trial showed that the BRAF inhibitor vemurafenib conferred significant survival benefit in patients with melanomas harboring BRAF-V600E, and vemurafenib has since been approved by both the United States Food and Drug Administration and the European Medicines Agency (10). However, most patients with melanomas harboring BRAF-V600E progress within 2 to 18 months of the initial response to vemurafenib (11). Unlike with the other kinase inhibitors, no acquired BRAF gatekeeper mutation caused by vemurafenib treatment has been reported in a clinical case; however, there are reports of resistance to vemurafenib mediated through
the reactivation of the mitogen-activated protein kinase (MAPK) signaling pathway and the activation of the AKT signaling pathway (12-22).

The MEK1-C121S mutation downstream of \textit{BRAF} is an acquired mutation that has recently been found to confer resistance to vemurafenib (12). This mutation also confers resistance to the allosteric mitogen-activated protein kinase kinase (MEK) inhibitor selumetinib (AZD6244) (12). MEK1-C121S suppresses the MAPK pathway inhibitory activity of vemurafenib and selumetinib (12). Therefore, to improve the clinical outcome of BRAF-V600E melanomas harboring MEK1-C121S, drugs that further inhibit the MAPK pathway are required.

E6201 is a novel MEK inhibitor that we developed (23), and a Phase I clinical trial of E6201 is ongoing in advanced solid tumors (Trial registration ID: NCT00794781). The chemical structure of E6201, a derivative of the natural product f152A1, is markedly different from the representative allosteric MEK inhibitors (Fig. 1). A docking simulation showed that f152A1 binds at the ATP binding site of MEK1 (24); therefore, E6201 is also likely to be an ATP-competitive MEK inhibitor with different pharmacological activities than those of allosteric MEK inhibitors. Furthermore, E6201 merits further investigation for the treatment of BRAF-V600E melanomas harboring MEK1-C121S because of its different MEK binding mode compared with allosteric
MEK inhibitors.

Here, we investigated the use of E6201 as a MEK inhibitor against BRAF-V600E melanoma harboring MEK1-C121S. We show that E6201 is an ATP-competitive MEK inhibitor that has potent growth inhibitory activity in BRAF-V600E melanoma compared with BRAF wild-type (WT) melanoma, although the compound inhibited the MAPK pathway both in BRAF-WT and BRAF-V600E melanoma. Furthermore, we demonstrate that E6201 is effective in a preclinical model against BRAF-V600E melanoma harboring MEK1-C121S and warrants further clinical investigation in a larger setting.
Materials and Methods

Compounds

Selumetinib and vemurafenib were provided by Wuxi AppTec (Shanghai, China).

Construction of pENTR_L1-MEK1-R5 ENTRY vector

pF1KE0668, a plasmid harboring the coding regions of the full-length MEK1 gene, was purchased from Kazusa DNA Research Institute. The MEK1 coding region was amplified using the following primer set: attB1_MEK1-Fwd., 5'-ggggacaagtttgtacaaaaagcaggctgccaccatgcccaagaagaagcgcagcggcatcc-3'; attB5r_MEK1-Rev., 5'-ggggacaacttacctcagcagctgccaccatgcccaagaagaagcgcagcggcatcc-3'. PCR reactions were performed in a total volume of 50 µL containing 10 µM of each primer, 0.5 ng of pF1KE0668 as the template DNA, and 1.25 U PrimeSTAR® GXL DNA Polymerase (TaKaRa Bio) according to the manufacturer's instructions. PCR reactions were incubated at 98°C for 1 min, followed by 30 cycles of 98°C for 10 s, 60°C for 15 s, and 68°C for 2 min, with a final extension period at 68°C for 5 min. The PCR products (1.3 kbp) were purified from agarose gels using a QIAEX II Gel Extraction Kit (QIAGEN). BP reactions were performed in a total volume of 10 µL containing 2 µL of BP
Clonase™ II Enzyme Mix, 150 ng pDONR P1-P5r (Invitrogen), and 100 ng PCR product. The reaction was incubated for 2 h at 25°C. After proteinase treatment, the mixture was transformed into _Escherichia coli_ TOP10 cells (Invitrogen). Colonies that grew on Lysogeny Broth (LB) plate (containing 50 μg/mL kanamycin) were picked and the insert was sequenced.

**Site-directed mutagenesis**

pENTR_L1-MEK1(C121S)-R5, a MEK1-C121S mutant ENTRY vector, was generated by site-directed mutagenesis with a PrimeSTAR® Mutagenesis Basal Kit (TaKaRa Bio) according to the manufacturer's instructions. The primers used were MEK1(C121S)-Fwd., 5'-catgagttcacttctgcactcgtgggc-3' and MEK1(C121S)-Rev., 5'-agagttggactcatgcagaacctgcagctc-3'. PCR reactions were performed in a total volume of 50 μL containing 10 μM of each primer, 10 pg of pENTR_L1-MEK1-R5 as the template DNA, and 25 μL of 2× PrimeSTAR Max Premix. PCR reactions were incubated at 98°C for 1 min, followed by 30 cycles of 98°C for 10 s, 55°C for 15 s, and 72°C for 50 s, with a final extension period at 72°C for 2 min. The PCR product (2.5 μL) was transformed into _E. coli_ TOP10 cells (Invitrogen) by using the heat shock method, and recombinants were selected on LB agar media supplemented with 50
μg/mL kanamycin. Two att-site sequences and the MEK1 region were checked by sequencing.

**Construction of pCLxIP_MEK1 (WT or C121S)-IRES-hmAG vectors**

(MEK1-internal ribosomal entry site–dependent Azami-Green protein expression vectors)

pCLxIP_MEK1-IRES-hmAG vector was constructed by using a MultiSite Gateway® Pro Kit (Invitrogen) according to manufacturer's instructions. pCLxIP-DEST (Cytomegalovirus promoter–based expression vector) and pENTR_L5-IRES-hmAG-L2 (IRES [internal ribosomal entry site]-dependent Azami-Green protein expression vector) were used in this study. These two vectors were created in-house. MultiSite LR reactions were performed in a 10-μL total volume containing 10 fmoles pENTR_L1-MEK1-R5, 10 fmoles pENTR_L5-IRES-hmAG-L2, 20 fmoles pCLxIP-DEST, and 2 μL LR II Clonase™ Plus (Invitrogen). The reaction was incubated overnight at 25°C. After proteinase treatment, the mixture was transformed into *E. coli* TOP10 cells (Invitrogen) by using the heat shock method, and recombinants were selected on LB agar media supplemented with 100 μg/mL ampicillin. The MEK1 and IRES-hmAG regions were checked by sequencing. A MEK1-C121S mutant
expression vector (pCLxIP_MEK1[C121S]-IRES-hmAG) was constructed via the same method. These expression vectors were designed so that the IRES-dependent Azami-Green gene and puromycin resistance gene were co-expressed with the MEK1 gene.

Cell lines and cell cultures

The human melanoma cell lines HMV-1 and SEKI were obtained from the Japanese Collection of Research Bioresources in 1987. The human melanoma cell lines HMCB, CHL-1, MDA-MB435S, and A375 were obtained from the American Type Culture Collection in 2008, 2008, 1998 and 2010 respectively. The melanoma cell line G-361 was obtained from DS Pharma Biomedical in 2010. A375/MEK1 WT and A375/MEK1-C121S cells were prepared by stable transfection of MEK1 WT- or C121S-expressing plasmids into parental A375 cells. HMV-1, SEKI, MDA-MB435S, and A375 cell lines were cultured in RPMI-1640 containing 10% FBS. HMCB and CHL-1 cell lines were cultured in Dulbecco’s modified Eagle’s medium containing 10% FBS. G-361 cell line was cultured in McCoy's medium containing 10% FBS. All cell lines were cultured at 37°C under a humidified atmosphere containing 5% CO₂, and authenticated by short-tandem repeat analysis.
BRAF DNA Sequencing

BRAF mutation status was assessed by using next-generation sequencing technology. Reverse transcribed cDNAs were prepared from HMV-1, HMCB, CHL-1, A375, SEKI, MDA-MB435S, and G361 cell lines and then used as templates for amplification of several genes of interest, including *BRAF*. Because it was difficult to amplify full-length BRAF cDNA, three pairs of primers that together cover the whole BRAF cDNA coding region were used (sense primer 1: GCCCGGGCTCTCGGTTATAAGATG, antisense primer 1: CCGTTCCCCAGAGATTCCAA; sense primer 2: TGCCATTCCGGAGGAGGTGT, antisense primer 2: GCCCATCAGGAGGAGGTG, antisense primer 2: GCCCATCAGGAGGAGGTG, antisense primer 3: CCCGGAACAGAAA GTAAAGCCTAG). PCR products from each cell line were mixed, and a library was constructed by using a Genomic DNA Sample Prep Kit (Illumina). Sequencing data were produced by using a Genome Analyzer II (Illumina) and Standard Cluster Generation and 36 Cycle Sequencing kits (Illumina).

Western blot analysis
Cells were incubated with a serial dilution of the test compounds in complete medium at 37°C for 24 h. Cells were lysed with cell lysis buffer (Cell Signaling Technology) containing 1 mM phenylmethylsulfonyl fluoride. Cellular debris was removed by centrifugation at 15,000 g for 20 min at 4°C. Western blotting was performed as described (25). Supernatants containing 10 μg of protein were subjected to SDS-PAGE under reducing conditions. The proteins were then transferred onto polyvinylidene fluoride membranes (Millipore) blocked with TBS containing 0.05% Tween-20 and 5% skim milk. The membranes were then probed with the following antibodies: anti-phospho Erk1/2 (Thr202/Tyr204), anti-ERK1/2 (Cell Signaling Technology), and anti-Cyclin D1 (BD Biosciences). Immunoreactive bands were visualized by detecting chemiluminescence with a ChemiDoc XRS gel imaging system (BIO-RAD).

Cell proliferation assay

Cells (2 × 10³ cells/100 μL/well) were seeded in 96-well culture plates. After overnight incubation at 37°C under a humidified atmosphere containing 5% CO₂, various concentrations of each compound were added, and cultured for 3 days. Then, 10 μL of WST-8 reagent (Dojindot) was added to each well, and absorbance was measured at 450 nm by using an Envision multilabel plate reader (Perkinelmer) and compared
with a reference measurement at 665 nm.

**In vitro MEK1 and MEK2 kinase assay**

An ELISA assay kit containing MEK1 and MEK2 recombinant protein was purchased from Carna Biosciences. The assay was performed according to Carna Biosciences’ internal protocol.

**Immunocytochemistry**

A375 cells were seeded (5 × 10⁵ cells/100 μL/well) in six-well plates the day before transfection. The cells were transfected with MEK1 expression vectors using lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. The following day, the cells were harvested by trypsinization and seeded (2.5 × 10⁴ cells/well) in 96-well imaging plates (BD Falcon). After overnight incubation at 37°C under a humidified atmosphere containing 5% CO₂, the cells were treated with serial dilutions of the test compounds for 24 h. For immunostaining, the cells were fixed with 2% paraformaldehyde for 45 min and permeabilized with 100% MeOH for 10 min. After blocking with 1% bovine serum albumin (BSA)/PBS for 3 h, the cells were incubated overnight with rabbit anti-Cyclin D1 (Abcam) in 0.1% BSA/PBS at 4°C.
After being washed with PBS, the cells were incubated with Alexa568-conjugated anti-rabbit IgG (Invitrogen) and 10 μg/ml Hoechst 33342 (Invitrogen) in 0.1% BSA/PBS for 1 h and then washed with PBS.

Image acquisition for each well was performed on an IN Cell Analyzer 1000 (GE Healthcare) by using a ×20 objective lens with 360-, 475-, and 555-nm excitation filters monitored through 460-, 517-, and 620-nm emission filters, respectively. The Cyclin D1 expression level of the vector-transfected Azami-Green-positive cells was determined by using the IN Cell Developer software (GE Healthcare). Images collected from 460-nm emission filters were used to define nuclear regions. The Azami-Green expression level and Cyclin D1 expression level of each cell were defined as the level of 517-nm and 620-nm intensity in the nuclear region, respectively. The mean and SD background value at 517-nm intensity was determined by analyzing wells that did not contain cells. Cells with Azami-Green expression levels higher than mean + 8 × SD of the background value at 517-nm intensity were defined as Azami-Green-positive. The Cyclin D1 expression level of each well was determined as the median Cyclin D1 expression level of Azami-Green-positive cells in the well.

Protein structure and docking simulations with MEK1 protein
1) Homology modeling of protein structure

The coordinates for human-MEK1 and the allosteric inhibitor G-894 complex were obtained from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (PDB entry code: 3V04) (26), and the protein structure was prepared by using the Maestro software package (Schrödinger). Hydrogen atoms were added and a brief relaxation was performed on each starting structure using the Protein Preparation module in the Maestro software. These coordinates were used for the selumetinib docking simulation. For the E6201 simulation, a MEK1 model was built by using the Prime homology modeling program (27, 28) and the human-ERK2 crystal structure (PDB entry code: 2E14) (29) coordinates as the template structure.

2) Induced-fit docking simulation

The Induced-Fit Docking (IFD) (30) module in the Maestro software was used. IFD uses the Glide docking program (31) to account for ligand flexibility, as well as the refinement module. The Prime algorithm is implemented in Glide to account for the flexibility of the receptor. Residues within 10 Å of the ligand poses were minimized to form suitable pose conformations at the binding site. Finally, each ligand was redocked to its corresponding low-energy protein structures and the resulting complexes were ranked according to their GlideScore. The IFD, given in kilocalories per mole, was
computed based on the GlideScore and a small fraction of the Prime energy by using the following formula: IFD Score = GlideScore + 0.05 Prime energy.
Results

E6201 is an ATP-competitive MEK1 and MEK2 inhibitor

To determine whether E6201 is an ATP-competitive or -noncompetitive MEK inhibitor, the inhibitory activity of E6201 on MEK1 and MEK2 was evaluated by using a cell-free kinase assay with various concentrations of ATP (Fig. 2). The IC₅₀ values of E6201 in the MEK1 cell-free assay were 0.020, 0.12, and 1.4 μM at ATP concentrations of 10, 30, and 100 μM, respectively. The IC₅₀ values in the MEK2 cell-free assay were 0.028, 0.067, and 0.70 μM at ATP concentrations of 10, 30, and 100 μM, respectively. The inhibitory activity of E6201 decreased with increasing ATP dose indicating that E6201 is an ATP-competitive MEK1 and MEK2 inhibitor.

Efficacy of E6201 against BRAF-V600E or -WT melanoma

BRAF-V600E melanoma is reported to be more sensitive than BRAF-WT melanoma to the MAPK pathway inhibition caused by BRAF inhibitors or allosteric MEK inhibitors (32, 33). To assess whether E6201 shows selective growth suppression in BRAF-V600E melanoma, we prepared a melanoma cell-line panel comprising three BRAF-WT (CHL-1, HMCB, and HMV-1) and four BRAF-V600E melanoma cell lines.
(G361, MDA-MB435, SEKI and A375). The *BRAF* mutation status of these cell lines was confirmed by DNA sequencing. Cell lines harboring the BRAF-V600E mutation were more sensitive to vemurafenib and selumetinib compared with BRAF-WT cell lines (Fig. 3A). E6201 also showed potent growth inhibitory activity in BRAF-V600E melanoma cell lines compared with BRAF-WT cell lines.

Next, we examined the MAPK pathway inhibitory activity of E6201 in a BRAF-V600E mutant (A375 and G361) and BRAF-WT melanoma (HMV-1) cell line (Fig. 3B and Supplementary Fig. S1). Vemurafenib inhibited extracellular signal-regulated kinase (ERK) phosphorylation in the BRAF-V600E mutant but not in the BRAF-WT melanoma (Fig. 3B), whereas selumetinib inhibited ERK phosphorylation in both the BRAF-V600E mutant and the BRAF-WT melanoma. E6201 also inhibited ERK phosphorylation in both the BRAF-V600E mutant and the BRAF-WT melanoma (Fig. 3B and Supplementary Fig. S1). E6201 inhibited ERK phosphorylation at a lower dose in the BRAF-V600E mutant than in the BRAF-WT melanoma; whereas selumetinib inhibited ERK phosphorylation in the BRAF-V600E mutant at approximately the same dose as in the BRAF-WT melanoma. These results indicate that the growth inhibitory activity of E6201 in melanoma cell lines harboring the BRAF-V600E mutation is mediated via MEK inhibition.
E6201 effectiveness on cells transiently or constitutively expressing MEK1-C121S

MEK1-C121S point mutation confers resistance to both vemurafenib and selumetinib (12). E6201 is an ATP-competitive MEK inhibitor that binds to MEK1 or MEK2 differently from allosteric MEK inhibitors. E6201 may therefore be effective against BRAF-V600E melanomas harboring MEK1-C121S.

To assess whether MEK1-C121S confers resistance to E6201 in melanoma cells, we transiently transfected A375 human melanoma cells with a MEK1-C121S-expressing vector. A375 was used because this cell line is reported to harbor the BRAF-V600E mutation and has frequently been used in similar experiments (12, 34). The presence of the BRAF-V600E mutation in A375 was confirmed by DNA sequencing. After treatment with the test compounds, transfected cells were immunocytochemically stained for Cyclin D1, which is a marker of the cytostatic effect of MAPK inhibitors (32, 35, 36). Only about 10% of cells were transfected with expression vectors in our transfection protocol, so to be able to identify transfected cells, we designed expression vectors for the co-expression of the IRES-dependent Azami-Green and MEK1 genes. We quantified the expression of Cyclin D1 in Azami-Green-negative and -positive (exogenous MEK1-WT/C121S-negative and -positive) cells separately by using an IN
Cell Analyzer high-content analysis system. Cyclin D1 expression decreased after treatment with 3.3 μM vemurafenib or 1.1 μM selumetinib in almost all of the Azami-Green-negative cells, but not in all of the Azami-Green-positive cells (Fig. 4A). However, Cyclin D1 expression decreased after treatment with 1.1 μM E6201 in both the Azami-Green-positive and -negative cells. Quantitatively, the Cyclin D1 expression inhibitory activities of vemurafenib and selumetinib in Azami-Green-positive cells (exogenous MEK1-C121S-positive cells) were remarkably lower compared with that in Azami-Green-negative cells (exogenous MEK1-C121S-negative cells) (Fig. 4B). The Cyclin D1 expression inhibitory activity of vemurafenib and selumetinib in Azami-Green-positive cells (exogenous MEK1-WT-positive cells) did not change compared with that in Azami-Green-negative cells (exogenous MEK1-WT-positive cells) (Supplementary Fig. S2). In contrast, the Cyclin D1 expression inhibitory activity of E6201 in Azami-Green-positive (exogenous MEK1-WT or C121S-positive) cells barely changed compared with Azami-Green-negative (exogenous MEK1-WT- or C121S-negative) cells (Fig. 4 and Supplementary Fig. S2). Moreover, the same result was obtained by using G361 (Supplementary Fig. S3). In A375 and G361, apoptosis was not inducted by MAPK inhibition. (Supplementary Fig. S4)

Next, to confirm the result of the transient transfection experiments regarding growth
inhibition, stable MEK1-WT or -C121S transfectants were established by using the A375 cell line. The growth inhibitory activities of vemurafenib and selumetinib in the MEK1-C121S transfectants were approximately 10 times weaker than in the MEK1-WT transfectants (Fig. 5A). However, that of E6201 in the MEK1-C121S transfectant was that same as that in the MEK1-WT transfectants (Fig. 5A). These results indicate that the MEK1-C121S mutation confers resistance to both vemurafenib and selumetinib but not E6201.

**Mechanism of acquired vemurafenib and selumetinib resistance and effectiveness of E6201 against MEK1-C121S melanoma**

To confirm the mechanism of vemurafenib and selumetinib resistance and the effectiveness of E6201 against MEK1-C121S mutant melanoma, ERK phosphorylation inhibitory activity was assessed in A375 MEK1-WT and -C121S transfectants (Fig. 5B). The ERK phosphorylation inhibitory activities of vemurafenib and selumetinib in the MEK1-C121S transfectant were approximately 10 times lower than those in the MEK1-WT transfectants. In contrast, the inhibitory activity of E6201 in the MEK1-C121S transfectants was the same as that in the MEK1-WT transfectants. These results indicate that vemurafenib and selumetinib resistance and the effectiveness of
E6201 against MEK1-C121S mutant melanoma is caused by inhibition of the MAPK pathway.

Both selumetinib and E6201 are MEK inhibitors; however, the MEK1-C121S mutation confers resistance only to selumetinib. To elucidate why this difference occurs, we simulated the docking process between selumetinib or E6201 and MEK1. The most energy-stable models are presented in Figure 6. Selumetinib binds to a hydrophobic pocket adjacent to the ATP binding site, like other allosteric inhibitors. (34) This hydrophobic pocket includes residues from both α-helix C and the activation loop. The binding of allosteric inhibitors within this pocket prevents the structural reorganization of α-helix C and other motifs, which generates a catalytically active MEK1 conformation. α-Helix C contains Cys_121, so Cys_121 mutations may cause resistance either by direct interference or by alteration of the C helix conformation. E6201, however, binds at the ATP binding site, meaning that Cys_121 mutations are unable to affect its inhibitory activity. These results indicate that the different actions of selumetinib and E6201 in BRAF-V600E melanoma result from the different binding modes to MEK1.
Discussion

On the basis of its MEK inhibitory activity, E6201 was shown here to be an ATP-competitive MEK inhibitor that is effective against BRAF-V600E melanoma in a preclinical setting. Furthermore, we showed that E6201 is effective in a preclinical model against BRAF-V600E melanoma harboring the MEK1-C121S mutation. Almost all of the MEK inhibitors previously reported are allosteric inhibitors, not ATP-competitive inhibitors (37). Our docking simulation showed that E6201 and selumetinib bind to different sites when they dock with MEK. These results suggest that the inhibitory mode of action of E6201 is different from that of allosteric MEK inhibitors and that E6201 merits further investigation in a clinical setting against both MEK-WT melanomas and melanomas harboring MEK with mutations at the allosteric site.

The MEK1-C121S mutation, which confers resistance to vemurafenib, increases MEK activity independently from BRAF and also confers resistance to the allosteric MEK inhibitor selumetinib (12). Our docking simulation showed that the MEK1-C121S mutation induced by vemurafenib treatment is located where selumetinib binds with MEK1, but is far from where E6201 binds with MEK1. This may account for the selumetinib resistance in BRAF-V600E melanoma harboring the MEK1-C121S
mutation. In contrast, E6201 suppressed ERK phosphorylation and inhibited cell growth equivalently in BRAF-V600E melanoma harboring MEK1-C121S and in WT melanoma cells. Thus, this is the first paper showing that E6201 is potentially effective against melanomas with acquired resistance to vemurafenib associated with the MEK1-C121S mutation. Further investigation in a clinical setting in a larger trial is warranted.

Our preclinical data suggest that E6201 warrants further study as a novel and potentially favorable therapeutic approach for melanoma. One option for using E6201 in the clinical setting is as second-line monotherapy after first-line treatment with vemurafenib in BRAF-V600E melanoma. For this approach, companion diagnostics to detect the MEK1-C121S mutation status are needed for appropriate patient stratification.

Another option for using E6201 in the clinical setting is in combination with vemurafenib as first-line therapy in metastatic melanomas harboring the BRAF-V600E mutation. A combination therapy clinical trial in melanoma using a BRAF inhibitor together with an allosteric MEK inhibitor is ongoing (Trial registration ID: NCT01072175, NCT01271803); however, this combination may not be effective upon acquisition of the MEK1-C121S mutation because the mutation confers resistance to
both BRAF inhibitors and allosteric MEK inhibitors. The combination of vemurafenib and E6201 may lead to a prolonged clinical response compared with vemurafenib monotherapy by inhibiting acquisition of the MEK1-C121S mutation.

We show here that the inhibitory activity of E6201 was higher in BRAF-V600E melanoma than in BRAF-WT melanoma, whereas that of selumetinib in BRAF-V600E was the same as in BRAF-WT. This inhibitory selectivity of E6201 against BRAF-WT and BRAF-V600E may lead to a broader therapeutic window because of its weak activity in BRAF-WT cells.

In conclusion, this preclinical study might lead to support the clinical development of E6201, an ATP-competitive MEK inhibitor, in BRAF inhibitor or allosteric MEK inhibitor resistant cancer.

Acknowledgements

We are grateful to Takashi Owa, Kenichi Nomoto, Toshimitsu Uenaka, and Akihiko Tsuruoka for coordinating the research team.
References


Figure legends

Figure 1. (A) Structure of E6201. (B) Structure of four allosteric MEK inhibitors.

Figure 2. (A) MEK1 and (B) MEK2 inhibitory activity of E6201 at different concentrations of ATP.

Figure 3. Effect of vemurafenib (BRAF inhibitor), selumetinib (allosteric MEK inhibitor), and E6201 (ATP-competitive MEK inhibitor) on BRAF-WT and -V600E melanoma cell lines. *BRAF* mutation status was confirmed by using DNA sequencing. (A) Growth inhibitory activity of each compound. White columns represent the result in BRAF-WT cell lines and black columns represent the result in BRAF-V600E cell lines. The growth IC₅₀ values of each compound in BRAF-WT melanoma cell lines were all above 1 μM. (B) MAPK pathway inhibitory activity of the test compounds.

Figure 4. Effect of vemurafenib, selumetinib, or E6201 on Cyclin D1 expression in
exogenous MEK1-C121S-positive or -negative A375 cells. (A) Cells were treated with 3.3 μM vemurafenib, 1.1 μM selumetinib, or 1.1 μM E6201. Hoechst is a total cell stain. Azami-Green-positive cells represent exogenous MEK1-C121S-expressing cells. Scale bar represents 100 μm. (B) Quantification of Cyclin D1 expression in exogenous MEK1-C121S-positive or -negative cells after treatment with the test compounds.

Figure 5. Effect of vemurafenib, selumetinib, or E6201 in MEK1-WT or -C121S transfectants. (A) Growth inhibitory activity of the test compounds. (B) MAPK pathway inhibitory activity of each compound.

Figure 6. (A) Most energy-stable complex models. Selumetinib binds to a hydrophobic pocket adjacent to the ATP binding site. (B) Most energy-stable complex model. E6201 binds at the ATP binding site.
Fig. 1.
Fig. 2.
**Fig. 3.**

(A) IC50 > 1.0 µM for Vemurafenib, Selumetinib, and E6201 in various cell lines.

(B) Western blot analysis showing pERK, ERK, Cyclin D1, and β-actin expression levels in HMV-1 (BRAF WT) and A375 (BRAF V600E) cells treated with different concentrations of Vemurafenib, Selumetinib, and E6201.
Fig. 4.
**Fig. 5.**
Molecular Cancer Therapeutics

Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model

Yusuke Narita, Kiyoshi Okamoto, Megumi Ikemori Kawada, et al.

Mol Cancer Ther Published OnlineFirst January 21, 2014.

Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-13-0667

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2014/01/22/1535-7163.MCT-13-0667.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.